INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Hims & Hers Health Inc. to Contact Law Firm

On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." Then, on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers, citing "Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk." The press release stated that Hims & Hers "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.''' The press release further stated that "[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China" which "FDA has never authorized or approved and which may contain unsafe and illicit foreign ingredients." 

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

If you own Hims & Hers Health, Inc. (NYSE: HIMS) stock, please contact Fletcher Moore by email at fletcher@fmoorelaw.com.

You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-action-notice-moore-law-pllc-encourages-investors-in-hims--hers-health-inc-to-contact-law-firm-302500435.html

SOURCE Moore Law PLLC